Zobrazeno 1 - 10
of 444
pro vyhledávání: '"Robert H Vonderheide"'
Autor:
Robert H Vonderheide, Andrew H Ko, Danny Khalil, Oliver Rosen, Robert A Wolff, James Francis, Samantha Bucktrout, Christopher R Cabanski, Silvia Boffo, Zev A Wainberg, Samik Upadhaya, Eileen M O’Reilly, Mark H O’Hara, George Fisher, Jamie Arnott, Ana Rosa Saez-Ibanez, Jay Campbell, Ute Dugan, Jill O’Donnell-Tormey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b601525223344c068784d6ee00423943
Autor:
Laurent Humeau, David Weiner, Robert H Vonderheide, Matthew P Morrow, Trevor McMullan, Anthony F Shields, Ashish V Chintakuntlawar, Kimberly A Kraynyak, Autumn J McRee, Jennifer M Johnson, Weijing Sun, Jan Pawlicki, Albert J Sylvester, Robert Samuels, Joseph J Kim, Jean D Boyer, Jeffrey M Skolnik
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine
Externí odkaz:
https://doaj.org/article/a019d7273be04e4cbb43557f12c156de
Autor:
Karin U Sorenmo, Erika Krick, Christina M Coughlin, Beth Overley, Thomas P Gregor, Robert H Vonderheide, Nicola J Mason
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e24167 (2011)
Cell-based active immunotherapy for cancer is a promising novel strategy, with the first dendritic cell (DC) vaccine achieving regulatory approval for clinical use last year. Manufacturing remains arduous, especially for DC vaccines, and the prospect
Externí odkaz:
https://doaj.org/article/dce81d50212b4062ae774bc9045000da
Autor:
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I
Externí odkaz:
https://doaj.org/article/5c32458bd77b40989a4cd89c57021223
Autor:
Fan Yang, Zhenqiang He, Hao Duan, Duo Zhang, Juehui Li, Huijuan Yang, Jay F. Dorsey, Wei Zou, S. Ali Nabavizadeh, Stephen J. Bagley, Kalil Abdullah, Steven Brem, Lin Zhang, Xiaowei Xu, Katelyn T. Byrne, Robert H. Vonderheide, Yanqing Gong, Yi Fan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune c
Externí odkaz:
https://doaj.org/article/b5c127f1aaa240298e7d6cf386dcde4f
Autor:
Payal D. Shah, Alexander C. Huang, Xiaowei Xu, Robert Orlowski, Ravi K. Amaravadi, Lynn M. Schuchter, Paul Zhang, Julia Tchou, Tina Matlawski, Amanda Cervini, Joanne Shea, Joan Gilmore, Lester Lledo, Karen Dengel, Amy Marshall, E. John Wherry, Gerald P. Linette, Andrea Brennan, Vanessa Gonzalez, Irina Kulikovskaya, Simon F. Lacey, Gabriela Plesa, Carl H. June, Robert H. Vonderheide, Tara C. Mitchell
Publikováno v:
Cancer Research Communications. 3:821-829
Purpose: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR)
Autor:
Amit Maity, Rosemarie Mick, Ramesh Rengan, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, Daniel A. Pryma, Dana M. Patsch, Alisha P. Maity, Andy J. Minn, Robert H. Vonderheide, John N. Lukens
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
We conducted a phase I dose-escalation trial of radiation with ipilimumab in patients with melanoma with ≥2 metastatic lesions. Here, we report the final full clinical analysis. Patients received RT (6 or 8 Gy x 2 or 3 doses) to a single lesion fol
Externí odkaz:
https://doaj.org/article/095b996398624a97bbe6f7d9f1fa3de8
Autor:
Robert H. Vonderheide, Adham S. Bear
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Like many tumor types, pancreatic ductal adenocarcinoma (PDAC) exhibits a rich network of tumor-derived cytokines and chemokines that drive recruitment of myeloid cells to the tumor microenvironment (TME). These cells, which include tumor-associated
Externí odkaz:
https://doaj.org/article/df56915ac00e41c5a7e766fe1adef617
Autor:
Samantha B. Kemp, Noah Cheng, Nune Markosyan, Rina Sor, Il-Kyu Kim, Jill Hallin, Jason Shoush, Liz Quinones, Natalie V. Brown, Jared B. Bassett, Nikhil Joshi, Salina Yuan, Molly Smith, William P. Vostrejs, Kia Z. Perez-Vale, Benjamin Kahn, Feiyan Mo, Timothy R. Donahue, Caius G. Radu, Cynthia Clendenin, James G. Christensen, Robert H. Vonderheide, Ben Z. Stanger
Publikováno v:
Cancer Discovery. 13:298-311
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1
Autor:
Kim A, Reiss, Rosemarie, Mick, Ursina, Teitelbaum, Mark, O'Hara, Charles, Schneider, Ryan, Massa, Thomas, Karasic, Rashmi, Tondon, Chioma, Onyiah, Mary Kate, Gosselin, Alyssa, Donze, Susan M, Domchek, Robert H, Vonderheide
Publikováno v:
Lancet Oncol
Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address chemotherapy resistance and cumulative toxicity. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in this se